Mutational Inactivation of <i>STAG2</i> Causes Aneuploidy in Human Cancer

David A. Solomon(Georgetown University), Taeyeon Kim(Georgetown University), Laura A. Díaz-Martínez(Howard Hughes Medical Institute), Joshlean Fair(Georgetown University), Abdel Elkahloun(National Institutes of Health), Brent T. Harris(Georgetown University), Jeffrey A. Toretsky(Georgetown University), Steven A. Rosenberg(National Institutes of Health), Neerav Shukla(Memorial Sloan Kettering Cancer Center), Marc Ladanyi(Memorial Sloan Kettering Cancer Center), Yardena Samuels(National Institutes of Health), C. David James(UCSF Helen Diller Family Comprehensive Cancer Center), Hongtao Yu(Howard Hughes Medical Institute), Jung-Sik Kim(Georgetown University), Todd Waldman(Georgetown University)
Science
August 18, 2011
Cited by 423Open Access
Full Text

Abstract

Most cancer cells are characterized by aneuploidy, an abnormal number of chromosomes. We have identified a clue to the mechanistic origins of aneuploidy through integrative genomic analyses of human tumors. A diverse range of tumor types were found to harbor deletions or inactivating mutations of STAG2, a gene encoding a subunit of the cohesin complex, which regulates the separation of sister chromatids during cell division. Because STAG2 is on the X chromosome, its inactivation requires only a single mutational event. Studying a near-diploid human cell line with a stable karyotype, we found that targeted inactivation of STAG2 led to chromatid cohesion defects and aneuploidy, whereas in two aneuploid human glioblastoma cell lines, targeted correction of the endogenous mutant alleles of STAG2 led to enhanced chromosomal stability. Thus, genetic disruption of cohesin is a cause of aneuploidy in human cancer.


Related Papers

No related papers found

Powered by citation graph analysis